Cantor Fitzgerald initiated coverage of Akero Therapeutics with an Overweight rating and $69 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AKRO:
- 3 Best Stocks to Buy Now, 9/19/2023, According to Top Analysts
- Akero Therapeutics price target raised to $60 from $50 at Evercore ISI
- Akero Therapeutics added to Analyst Focus List at JPMorgan
- Akero Therapeutics price target raised to $62 from $49 at JPMorgan
- Akero Therapeutics to Present at Upcoming Healthcare Conferences in September